Israeli court rejects Taro's call for special tender offer by Sun
This article was originally published in Scrip
A Tel Aviv court has rejected Taro Pharmaceutical Industries' contention that Sun Pharmaceutical Industriesshould have conducted a "special tender offer" under Israeli Law. This paves the way for the completion of a previously announced tender offer by Sun for all outstanding ordinary shares of Taro. Sun's tender offer for Taro follows an acrimonious dispute over a merger pact between the two companies that Taro called off in May.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.